New criteria enhances prostate surgery outcomes

by Sophie Hepburn
New criteria enhances prostate surgery outcomes
Each year in Australia, close to 3,300 men die of prostate cancer and around 20,000 new cases are diagnosed (PCRA). Credit: iStock

A new method to pre-operatively identify transition zone prostate cancer has enabled surgeons to adopt a more targeted surgical approach to treatment.

The set of criteria for examining biopsy specimens was developed by researchers funded and supported by the West Australian Urological Research Organisation.

The prostate gland, although considered a single organ, is composed of different anatomical zones (peripheral, transition, and central), and tumours arising in these regions differ in biological behaviour.

The transition zone (Tz) is situated furthest away from the rectum through which biopsies are obtained, and identification of Tz cancer on biopsy almost always indicates a large cancer that tends to spread toward the bladder neck.

Co-author Stephen Lee from Uropath Pty Ltd, Western Australia, says that "prior to this study there was no way of distinguishing Tz cancer from tumours occurring in the other prostatic zones on pre-operative biopsy, and therefore no way to safely modify the surgical approach".

"About one-quarter of cancers originate in the Tz and these tumours are far less likely to involve the nerves important for erectile function," Dr Lee says.

"Further, these tumours invade the bladder neck and wider resection of this structure is needed to ensure cure."

The new biopsy test criterion identifies the Tz , pre-operatively, allowing surgeons to change their surgical approach to best retain full erectile function and recovery.

The method used for Tz tumour identification, uses a specific tissue fixative (Solufix) developed in WA over a decade ago.

The fixative preserves structures called prostate secretory granules (PSGs), which are retained in Tz tumours but not in cancers from the peripheral or central zone.

They evaluated four morphologic features to predict origins of tumours; the percentage of tumour cells retaining PSG, and the percentage of cells with pale cytoplasm, columnar shape, and luminal secretions.

The amount of PSG found in tumours was the most sensitive marker for Tz tumour origin in 44 surgically removed tumours and in 135 biopsy specimens preserved in Solufix.

When a PSG content of >50 per cent was combined with one of the other parameters the ability to correctly identify tumours that were not of Tz origin increased.

The results showed that testing for a combination of PSG content of >50 per cent (major criteria) with one of either; >30 per cent columnar cells, >30 per cent pale cells, or secretions (minor criteria) in biopsy specimens is a reliable predictor of Tz origin.

The group now successfully apply this set of criteria in routine practice.

add to favorites email to friend print save as pdf

Related Stories

Scientists make brain tumours glow

Apr 24, 2013

Stereotactic needle biopsies are an established standard procedure in the diagnostic identification of brain lymphomas and certain brain tumours (gliomas). Up until now the tissue samples removed had to be ...

Mutated stem cells trigger pituitary tumours in children

Oct 07, 2013

(Medical Xpress)—A type of pituitary tumour known as craniopharyngioma appears to form via a different mechanism to that thought to occur in more common tumours, according to a paper in the journal Cell St ...

Forcing cancer to digest itself

Sep 12, 2013

When tumour cells no longer degrade themselves, cancer may develop. Using black skin cancer as an example, Bern Researchers have now shown that a protein plays an important role in the process of degradation ...

Recommended for you

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.